Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 17/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623436 | 1.00 | KCNE1 (1.00) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL29963612 | 1.00 | KCNE1 (1.00) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL4622354 | 1.00 | KCNE1 (1.00) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL8483344 | 0.96 | KCNE1 (0.92) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL6938828 | 0.96 | KCNE1 (0.92) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL6938824 | 0.96 | KCNE1 (0.92) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL6932256 | 0.89 | KCNE1 (1.00) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL6935433 | 0.89 | KCNE1 (1.00) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL6932421 | 0.89 | KCNE1 (0.80) | KCNE1KCNQ1KCNH2MEN1CYP1A2 | |
| SCHEMBL6932423 | 0.89 | KCNE1 (0.80) | KCNE1KCNQ1KCNH2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020055537-A1 | Use of inhibitors of the KQT1 channel and methods of controlling and treating diseases caused by helminths and ectoparasites | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-09 | — | — | US | claimed |
| US-6335363-B1 | ADMINISTERING 4-(SULFONYLAMINO-)-CHROMANE DERIVATIVE AS INSECTICIDE, NEMATOCIDE, FUNGICIDE OR PESTICIDE FOR CROP PROTECTION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | claimed |
| EP-1140042-B1 | UTILIZATION OF INHIBITORS OF THE KQT1 CHANNEL IN ORDER TO PRODUCE A MEDICAMENT FOR TREATING DISEASES WHICH ARE CAUSED BY PARASITIC HELMINTHS AND ECTOPARASITES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-0913396-B1 | Sulphonamide substituted benzopyran derivatives, process of preparation, their use as medicines and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-6008245-A | TREATMENT OF PROPHYLAXIS AND CARDIOVASCULAR DISORDERS, IN PARTICULAR ARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL DISORDERS, DIARRHEAL DISEASES | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 1999-12-28 | — | — | US | disclosed |
| EP-0913396-A2 | Sulphonamide substituted benzopyran derivatives, process of preparation, their use as medicines and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055537-A1 | Use of inhibitors of the KQT1 channel and methods of controlling and treating diseases caused by helminths and ectoparasites | KCNQ1, KCNQ2, KCNQ3 | KCNE1 17/4885KCNQ1 1/4885KCNH2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.